West Virginia is currently home to 321 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Morgantown, Charleston, Huntington and Wheeling. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
NCT06380751
Recruiting
The primary objective of the study is to measure efficacy of saruparib (AZD5305) plus camizestrant compared with physician's choice CDK4/6i plus ET in patients with BRCA1, BRCA2, or PALB2m, HR-positive, HER2-negative (defined as IHC 0, 1+, 2+/ ISH non-amplified) advanced breast cancer
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Research Site, Morgantown, West Virginia
Conditions: Advanced Breast Cancer
Register for Updates
A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-severe Systemic Disease Activity
NCT06104124
Recruiting
Primary Objective: To evaluate the effect of dazodalibep on systemic manifestations of Sjögren's Syndrome (SS) in participants with moderate-to-severe systemic disease activity. Secondary Objectives: 1. To evaluate the effect of dazodalibep on patient reported outcomes (PROs) in participants with SS. 2. To evaluate the safety and tolerability of dazodalibep in participants with SS
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Rheumatology and Pulmonary Clinic, Beckley, West Virginia
Conditions: Sjogren's Syndrome
Register for Updates
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
NCT05503797
Recruiting
The objective of this Master Protocol is to evaluate the efficacy and safety of plixorafenib in participants with locally advanced or metastatic solid tumors, or recurrent or progressive primary central nervous system (CNS) tumors harboring BRAF fusions, or in participants with rare BRAF V600-mutated solid tumors, melanoma, thyroid, or recurrent primary CNS tumors.
Gender:
ALL
Ages:
10 years and above
Trial Updated:
05/13/2025
Locations: West Virginia University Health Sciences Campus, Morgantown, West Virginia
Conditions: Cancer Harboring BRAF Alterations, HGG, LGG, Solid Tumors, Melanoma BRAF V600E/K Mutated, Thyroid Cancer
Register for Updates
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
NCT05125302
Recruiting
Migraine is a common neurological disorder typically characterized by attacks of throbbing, moderate to severe headache, often associated with nausea, vomiting, and sensitivity to light and sound. Migraine is extremely common and disabling in children. The purpose of this study is to evaluate how safe and effective ubrogepant is in the acute treatment of migraine in children and adolescents. Ubrogepant is a drug approved for the acute treatment of migraine in adults. Children and adolescents (a... Read More
Gender:
ALL
Ages:
Between 6 years and 17 years
Trial Updated:
05/13/2025
Locations: Frontier Clinical Research - Kingwood /ID# 231914, Kingwood, West Virginia
Conditions: Migraine
Register for Updates
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
NCT06616584
Recruiting
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody that stimulates the immune system by blocking the PD-1 pathway. Tumors use the PD-1 pathway to escape attacks from the immune system. By blocking the PD-1 pathway, cemi... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: West Virginia University Healthcare, Morgantown, West Virginia
Conditions: Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
A Study to Investigate Efficacy and Safety of TOUR006 in Participants 18 to 80 Years of Age With Thyroid Eye Disease
NCT06088979
Recruiting
Phase 2b trial of TOUR006 in Thyroid Eye Disease (TED) to evaluate 20mg and 50mg doses against placebo given by a subcutaneous injection every eight weeks to TED patients who are in the active inflammatory phase of disease.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/12/2025
Locations: University of West Virginia Site - 0113, Morgantown, West Virginia
Conditions: Thyroid Eye Disease
Register for Updates
Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body
NCT04142437
Recruiting
In this observational study researcher want to learn more about the effectiveness of drug VITRAKVI (generic name: larotrectinib) and how well the drug is tolerated during routine use in patients with TRK fusion cancer which is locally advanced or spread from the place where it started to other places in the body. TRK fusion cancer is a term used to describe a variety of common and rare cancers that are caused by a change to the NTRK (Neurotrophic Tyrosine Kinase) gene called a fusion. During thi... Read More
Gender:
ALL
Ages:
All
Trial Updated:
05/12/2025
Locations: West Virginia University, Morgantown, West Virginia
Conditions: Locally Advanced or Metastatic Solid Tumor Harboring an NTRK Gene Fusion
Register for Updates
Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer
NCT03488693
Recruiting
The purpose of this study is to compare the effects on low risk breast cancer receiving usual care that includes regional radiation therapy, with receiving no regional radiation therapy. Researchers want to see if not giving this type of radiation treatment works as well at preventing breast cancer from coming back.
Gender:
FEMALE
Ages:
35 years and above
Trial Updated:
05/12/2025
Locations: West Virginia University Healthcare, Morgantown, West Virginia
Conditions: Breast Cancer
Register for Updates
S1501 Carvedilol in Preventing Cardiac Toxicity in Patients With Metastatic HER-2-Positive Breast Cancer
NCT03418961
Recruiting
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: WVUH-Berkely Medical Center, Martinsburg, West Virginia
Conditions: Cardiotoxicity, HER2/Neu Positive, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Register for Updates
Pregnancy Surveillance Program of Patients Exposed to Epidiolex/Epidyolex During Pregnancy
NCT06113237
Recruiting
The purpose of this study is to evaluate pregnancy-related health outcomes in participants who are exposed to Epidiolex/Epidyolex during pregnancy and their infant up to 12 months of life.
Gender:
FEMALE
Ages:
All
Trial Updated:
05/09/2025
Locations: United Biosource LLC, Morgantown, West Virginia
Conditions: Maternal Complications, Pregnancy Complication, Birth Outcomes, Adverse, Pregnancy
Register for Updates
Pharmacokinetic and Safety Study of Oral Lofexidine in Neonates Experiencing Opioid Withdrawal Due to Intrauterine Exposure to Opioids
NCT06047834
Recruiting
A randomized, open-label, controlled, ascending dose cohort, PK, and safety study assessing standard of care (i.e., non-pharmacologic measures and morphine when indicated) with or without lofexidine for the treatment of opioid withdrawal symptoms in neonates due to intrauterine exposure to opioids, described as neonatal opioid withdrawal syndrome (NOWS) or neonatal abstinence syndrome (NAS). This study has been designed to assess the pharmacokinetics (PK) and safety of the lofexidine in neonate... Read More
Gender:
ALL
Ages:
Between 0 hours and 6 days
Trial Updated:
05/09/2025
Locations: Marshall Health, Huntington, West Virginia
Conditions: Opioid Withdrawal (Disorder)
Register for Updates
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma.
NCT05763121
Recruiting
This study will assess the efficacy and safety of dexpramipexole as an adjunctive oral therapy in participants with inadequately controlled asthma with an eosinophilic phenotype and a history of asthma exacerbations.
Gender:
ALL
Ages:
Between 12 years and 99 years
Trial Updated:
05/09/2025
Locations: Research Site 20001-480, Barboursville, West Virginia
Conditions: Eosinophilic Asthma, Asthma; Eosinophilic, Asthma
Register for Updates